HK1215932A1 - 調節食慾的方法 - Google Patents

調節食慾的方法

Info

Publication number
HK1215932A1
HK1215932A1 HK16103907.8A HK16103907A HK1215932A1 HK 1215932 A1 HK1215932 A1 HK 1215932A1 HK 16103907 A HK16103907 A HK 16103907A HK 1215932 A1 HK1215932 A1 HK 1215932A1
Authority
HK
Hong Kong
Prior art keywords
modulating appetite
appetite
modulating
Prior art date
Application number
HK16103907.8A
Other languages
English (en)
Inventor
Samuel Norbert Breit
Asne Rhoda Bauskin
Original Assignee
St Vincents Hospital Sydney Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1215932(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2004901957A external-priority patent/AU2004901957A0/en
Application filed by St Vincents Hospital Sydney Ltd filed Critical St Vincents Hospital Sydney Ltd
Publication of HK1215932A1 publication Critical patent/HK1215932A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK16103907.8A 2004-04-13 2007-05-23 調節食慾的方法 HK1215932A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2004901957A AU2004901957A0 (en) 2004-04-13 Method for modulating appetite

Publications (1)

Publication Number Publication Date
HK1215932A1 true HK1215932A1 (zh) 2016-09-30

Family

ID=35149777

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16103907.8A HK1215932A1 (zh) 2004-04-13 2007-05-23 調節食慾的方法
HK12108474.4A HK1168274A1 (zh) 2004-04-13 2007-05-23 抑製劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12108474.4A HK1168274A1 (zh) 2004-04-13 2007-05-23 抑製劑

Country Status (12)

Country Link
US (6) US8192735B2 (zh)
EP (4) EP2774620A1 (zh)
JP (4) JP5448338B2 (zh)
CA (2) CA2905125C (zh)
CY (1) CY1115731T1 (zh)
DK (2) DK2441466T3 (zh)
ES (3) ES2555956T3 (zh)
HK (2) HK1215932A1 (zh)
PL (2) PL2929891T3 (zh)
PT (2) PT2929891T (zh)
SI (1) SI2441466T1 (zh)
WO (1) WO2005099746A1 (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099746A1 (en) * 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Method for modulating appetite
WO2008015254A2 (en) * 2006-08-04 2008-02-07 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
CA2694863A1 (en) * 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
US20100266707A1 (en) * 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
EP2350669B9 (en) 2008-10-31 2014-06-11 St Vincent's Hospital Sydney Limited Methods of prognosis in chronic kidney disease
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2830646B1 (en) * 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2013322628B2 (en) 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
EA038645B1 (ru) 2012-12-21 2021-09-28 Авео Фармасьютикалз, Инк. Антитела к gdf15
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
MA38873B1 (fr) 2013-07-31 2018-11-30 Amgen Inc Constructions contenant le facteur 15 de différentiation de croissance (gdf-15)
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
DK3122775T3 (da) 2014-03-26 2020-02-03 Univ Wuerzburg J Maximilians Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer
MX2016016826A (es) * 2014-06-20 2017-08-28 Aveo Pharmaceuticals Inc Tratamiento de la enfermedad renal cronica y otra disfuncion renal utilizando un modulador gdf15.
WO2015196142A1 (en) * 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
EP3157942B1 (en) * 2014-06-23 2020-06-17 Novartis AG Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US9272019B2 (en) 2014-06-24 2016-03-01 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
SG11201700378PA (en) 2014-07-30 2017-02-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
EP3851122A1 (en) * 2014-09-25 2021-07-21 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US20170334971A1 (en) * 2014-12-22 2017-11-23 Novo Nordisk A/S Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
WO2017055612A1 (en) 2015-10-02 2017-04-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
EA201890850A1 (ru) 2015-10-02 2018-09-28 Юлиус-Максимилианс-Универзитет Вюрцбург Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
EP3425392A4 (en) * 2016-02-29 2020-02-05 Public University Corporation Yokohama City University METHOD FOR DETECTING CASTRATION-RESISTANT PROSTATE CANCER AND REAGENT REAGENT
IL261666B2 (en) 2016-03-31 2024-09-01 Ngm Biopharmaceuticals Inc Related proteins and methods of using them
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
WO2017202936A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and use thereof
CA3038846A1 (en) * 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
AU2017371382A1 (en) * 2016-12-06 2019-06-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019004550A1 (ko) * 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
CN111954537A (zh) 2018-04-09 2020-11-17 美国安进公司 生长分化因子15融合蛋白
BR112021003173A2 (pt) 2018-08-20 2021-05-11 Pfizer Inc. anticorpos anti-gdf15, composições e métodos de uso
US20200152330A1 (en) * 2018-11-13 2020-05-14 CurieAI, Inc. Scalable Personalized Treatment Recommendation
WO2021107603A2 (en) 2019-11-26 2021-06-03 Yuhan Corporation Long-acting gdf15 fusion protein and pharmaceutical composition comprising same
US20240182585A1 (en) 2021-03-31 2024-06-06 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
AU2022278933A1 (en) 2021-05-21 2023-12-07 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
WO2022245179A1 (en) 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
CA3228576A1 (en) 2021-08-10 2023-02-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE69637844D1 (de) 1995-06-22 2009-04-09 St Vincent S Hospital Sidney L Neues tgf-beta-ahnliches cytokin
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
DE60142372D1 (de) 2000-04-20 2010-07-22 St Vincents Hosp Sydney Diagnostischer Assay mit makrophagenhemmendem Zytokin-1 (MIC-1)
AU2001288770A1 (en) * 2000-09-08 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
US7157235B2 (en) * 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
WO2005099746A1 (en) 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Method for modulating appetite
PT1844337E (pt) * 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
US20100204123A1 (en) 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease

Also Published As

Publication number Publication date
EP2441466A1 (en) 2012-04-18
ES2788868T3 (es) 2020-10-23
JP2013209376A (ja) 2013-10-10
EP1734986A4 (en) 2009-07-22
PL2441466T3 (pl) 2015-01-30
EP2929891A1 (en) 2015-10-14
EP2929891B1 (en) 2020-03-11
DK2441466T3 (da) 2014-10-27
US20090004181A1 (en) 2009-01-01
EP2441466B1 (en) 2014-07-23
ES2518865T3 (es) 2014-11-05
DK2929891T3 (da) 2020-05-11
PT2929891T (pt) 2020-04-08
JP5448338B2 (ja) 2014-03-19
US20210340243A1 (en) 2021-11-04
PT2441466E (pt) 2014-09-09
EP2774620A1 (en) 2014-09-10
CA2905125A1 (en) 2005-10-27
JP2007532586A (ja) 2007-11-15
SI2441466T1 (sl) 2015-01-30
CA2561877C (en) 2017-03-14
JP5767667B2 (ja) 2015-08-19
EP1734986B1 (en) 2015-11-11
CY1115731T1 (el) 2017-01-25
EP1734986A1 (en) 2006-12-27
US20110123454A1 (en) 2011-05-26
ES2555956T3 (es) 2016-01-11
US8946146B2 (en) 2015-02-03
US20150183861A1 (en) 2015-07-02
US8192735B2 (en) 2012-06-05
US20160289320A1 (en) 2016-10-06
WO2005099746A1 (en) 2005-10-27
PL2929891T3 (pl) 2020-08-24
US20180346560A1 (en) 2018-12-06
JP2014051511A (ja) 2014-03-20
HK1168274A1 (zh) 2012-12-28
JP2011190262A (ja) 2011-09-29
JP5806275B2 (ja) 2015-11-10
CA2905125C (en) 2017-02-07
CA2561877A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
PT2929891T (pt) Método para modulação do apetite
ZA200704202B (en) Method for preparing n-phenylpyrazole-1-carboxamides
GB0420061D0 (en) Method
GB0402639D0 (en) Method
GB0422733D0 (en) Method
GB0410478D0 (en) Method
GB0415009D0 (en) Method
GB0419419D0 (en) Method
GB0422730D0 (en) Method
GB0418651D0 (en) Method
GB0412659D0 (en) Method
GB0412672D0 (en) Method
GB0414787D0 (en) Method
GB0419405D0 (en) Method
GB0405751D0 (en) Method
TWI315261B (en) Method for transferring-printing
AU2004901957A0 (en) Method for modulating appetite
GB0415081D0 (en) Method
GB0413714D0 (en) Method
ZA200500148B (en) Method for nano-sizing
GB0406989D0 (en) Method
GB0410872D0 (en) Method
GB0406833D0 (en) Method
GB0405730D0 (en) Method
GB0405597D0 (en) Method